Donald E. Saunders Sells 500 Shares of Chemed Corp. (CHE) Stock
Chemed Corp. (NYSE:CHE) Director Donald E. Saunders sold 500 shares of the company’s stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $149.56, for a total transaction of $74,780.00. Following the transaction, the director now directly owns 10,286 shares of the company’s stock, valued at approximately $1,538,374.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Chemed Corp. (NYSE:CHE) opened at 145.80 on Thursday. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of 23.27 and a beta of 1.25. Chemed Corp. has a 52 week low of $124.77 and a 52 week high of $159.76. The firm has a 50-day moving average price of $140.50 and a 200-day moving average price of $136.95.
Chemed Corp. (NYSE:CHE) last posted its earnings results on Wednesday, October 26th. The company reported $1.73 EPS for the quarter, missing the Zacks’ consensus estimate of $1.82 by $0.09. The business earned $392.61 million during the quarter, compared to the consensus estimate of $270.44 million. Chemed Corp. had a return on equity of 23.95% and a net margin of 6.77%. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.78 EPS. Analysts anticipate that Chemed Corp. will post $7.25 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Stockholders of record on Monday, November 14th will be paid a $0.26 dividend. The ex-dividend date is Wednesday, November 9th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.71%. Chemed Corp.’s dividend payout ratio (DPR) is currently 16.59%.
Several equities research analysts have recently commented on the company. JMP Securities reissued a “hold” rating on shares of Chemed Corp. in a report on Sunday, September 4th. RBC Capital Markets restated a “sector perform” rating and issued a $162.00 price target (up previously from $136.00) on shares of Chemed Corp. in a research note on Wednesday, July 27th. Royal Bank Of Canada lowered their price objective on Chemed Corp. from $162.00 to $148.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 1st. Zacks Investment Research upgraded Chemed Corp. from a “hold” rating to a “buy” rating and set a $167.00 price objective on the stock in a research report on Thursday, July 28th. Finally, Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $155.00 price objective on shares of Chemed Corp. in a research report on Tuesday, September 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $154.50.
Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in Chemed Corp. by 90.4% in the first quarter. BlackRock Inc. now owns 1,152 shares of the company’s stock worth $156,000 after buying an additional 547 shares during the period. State Street Corp increased its position in Chemed Corp. by 3.2% in the first quarter. State Street Corp now owns 420,203 shares of the company’s stock worth $56,917,000 after buying an additional 13,149 shares during the period. UBS Group AG increased its position in Chemed Corp. by 125.8% in the first quarter. UBS Group AG now owns 14,147 shares of the company’s stock worth $1,917,000 after buying an additional 7,883 shares during the period. Goldman Sachs Group Inc. increased its position in Chemed Corp. by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 48,053 shares of the company’s stock worth $6,509,000 after buying an additional 4,640 shares during the period. Finally, Renaissance Technologies LLC increased its position in Chemed Corp. by 72.3% in the first quarter. Renaissance Technologies LLC now owns 148,200 shares of the company’s stock worth $20,074,000 after buying an additional 62,200 shares during the period. Hedge funds and other institutional investors own 98.61% of the company’s stock.
About Chemed Corp.
Chemed Corporation operates and divests subsidiaries engaged in diverse business activities. The Company operates its business in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Stock Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related stocks with our FREE daily email newsletter.